Clinical Trials
2 trialsNCT07134556 2026-05-01
ADJUNCT
MedSIR
Phase 2 Withdrawn
NCT07328490 2026-04-28
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn